CINXE.COM

<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><link rel="icon" type="image/png" href="https://assets.brighttalk.com/images/favicon.ico"/><link rel="apple-touch-icon" href="https://assets.brighttalk.com/images/favicon.ico"/><link rel="canonical" href="https://www.brighttalk.com/webcast/10519/623717"/><title>Current Status and Overview of the RMM and Endotoxin Microbiology USP Chapters under Development</title><meta name="description" content="Jay Bolden, Senior Director, Eli Lilly and Company Global Quality Laboratories. Presenting: An Overview of Recent USP Bacterial Endotoxins Standards Dev..."/><meta property="og:type" content="website"/><meta name="og:title" property="og:title" content="Current Status and Overview of the RMM and Endotoxin Microbiology USP Chapters under Development"/><meta name="og:description" property="og:description" content="Jay Bolden, Senior Director, Eli Lilly and Company Global Quality Laboratories. Presenting: An Overview of Recent USP Bacterial Endotoxins Standards Development Dr David Roesti, PhD. Microbiologist/Facilitator QA/QC at Novartis Pharma AG. Presenting: Overview and Future Plans of the USP Rapid Microbiological Methods Subcommittee Veronika Wills, Manager, Technical Services at Associates of Cape Cod, Inc Presenting: Early Implementation of Recombinant Cascade Reagent PyroSmart NextGen® in Line With USP <86> Nicola Reid, Associate Director of Endotoxin Products, Charles River Presenting: A 3-Step Validation Blueprint for Recombinant Method Implementation Lamin Jallow, Microbiology Technology Specialist at Merck KGaA Presenting: Early detection of microbial contaminants in cell-based products using the Milliflex® Rapid System Félix Montero-Julian, Scientific Director of Pharma Quality Control at bioMérieux Presenting: Implementation of BACT/ALERT® 3D in light of the USP <72> Chapter: Respiration-Based Microbiological Methods for the Detection of Contamination in Short-Life Products Followed by a live Questions and Answers session."/><meta property="og:site_name" content="BrightTALK"/><meta property="og:url" content="https://www.brighttalk.com/webcast/10519/623717"/><meta name="brighttalk-channel-id" content="10519"/><meta name="brighttalk-page-architecture" content="react"/><meta name="brighttalk-page-name" content="webcast"/><meta name="brighttalk-content-status" content="upcoming"/><meta name="brighttalk-community" content="Life Sciences"/><meta name="brighttalk-community-parent" content="Healthcare"/><meta name="twitter:card" content="summary"/><meta name="twitter:title" content="Current Status and Overview of the RMM and Endotoxin Microbiology USP Chapters under Development"/><meta name="twitter:description" content="Jay Bolden, Senior Director, Eli Lilly and Company Global Quality Laboratories. Presenting: An Overview of Recent USP Bacterial Endotoxins Standards Development Dr David Roesti, PhD. Microbiologist/Facilitator QA/QC at Novartis Pharma AG. Presenting: Overview and Future Plans of the USP Rapid Microbiological Methods Subcommittee Veronika Wills, Manager, Technical Services at Associates of Cape Cod, Inc Presenting: Early Implementation of Recombinant Cascade Reagent PyroSmart NextGen® in Line With USP <86> Nicola Reid, Associate Director of Endotoxin Products, Charles River Presenting: A 3-Step Validation Blueprint for Recombinant Method Implementation Lamin Jallow, Microbiology Technology Specialist at Merck KGaA Presenting: Early detection of microbial contaminants in cell-based products using the Milliflex® Rapid System Félix Montero-Julian, Scientific Director of Pharma Quality Control at bioMérieux Presenting: Implementation of BACT/ALERT® 3D in light of the USP <72> Chapter: Respiration-Based Microbiological Methods for the Detection of Contamination in Short-Life Products Followed by a live Questions and Answers session."/><meta name="twitter:site" content="BrightTALK"/><meta name="twitter:creator" content=""/><meta property="og:image" content="https://cdn.brighttalk.com/ams/california/images/communication/623717/image_1014649.jpg?width=640&height=360"/><meta name="twitter:image" content="https://cdn.brighttalk.com/ams/california/images/communication/623717/image_1014649.jpg?width=640&height=360"/><meta name="viewport" content="initial-scale=1.0, width=device-width"/><meta name="robots" content="index,follow"/><script type="application/ld+json">{"@context":"https://schema.org","@type":"Event","name":"Current Status and Overview of the RMM and Endotoxin Microbiology USP Chapters under Development","description":"Jay Bolden, Senior Director, Eli Lilly and Company Global Quality Laboratories. Presenting:\nAn Overview of Recent USP Bacterial Endotoxins Standards Development\n\nDr David Roesti, PhD. Microbiologist/Facilitator QA/QC at Novartis Pharma AG. Presenting:\nOverview and Future Plans of the USP Rapid Microbiological Methods Subcommittee\n\nVeronika Wills, Manager, Technical Services at Associates of Cape Cod, Inc\nPresenting: Early Implementation of Recombinant Cascade Reagent PyroSmart NextGen® in Line With USP <86>\n\nNicola Reid, Associate Director of Endotoxin Products, Charles River\nPresenting: A 3-Step Validation Blueprint for Recombinant Method Implementation\n\nLamin Jallow, Microbiology Technology Specialist at Merck KGaA\nPresenting: Early detection of microbial contaminants in cell-based products using the Milliflex® Rapid System\n\nFélix Montero-Julian, Scientific Director of Pharma Quality Control at bioMérieux\nPresenting: Implementation of BACT/ALERT® 3D in light of the USP <72> Chapter: Respiration-Based Microbiological Methods for the Detection of Contamination in Short-Life Products\n\nFollowed by a live Questions and Answers session.","about":"Jay Bolden, Senior Director, Eli Lilly and Company Global Quality Laboratories. Presenting:\nAn Overview of Recent USP Bacterial Endotoxins Standards Development\n\nDr David Roesti, PhD. Microbiologist/Facilitator QA/QC at Novartis Pharma AG. Presenting:\nOverview and Future Plans of the USP Rapid Microbiological Methods Subcommittee\n\nVeronika Wills, Manager, Technical Services at Associates of Cape Cod, Inc\nPresenting: Early Implementation of Recombinant Cascade Reagent PyroSmart NextGen® in Line With USP <86>\n\nNicola Reid, Associate Director of Endotoxin Products, Charles River\nPresenting: A 3-Step Validation Blueprint for Recombinant Method Implementation\n\nLamin Jallow, Microbiology Technology Specialist at Merck KGaA\nPresenting: Early detection of microbial contaminants in cell-based products using the Milliflex® Rapid System\n\nFélix Montero-Julian, Scientific Director of Pharma Quality Control at bioMérieux\nPresenting: Implementation of BACT/ALERT® 3D in light of the USP <72> Chapter: Respiration-Based Microbiological Methods for the Detection of Contamination in Short-Life Products\n\nFollowed by a live Questions and Answers session.","startDate":"2024-12-04T14:30:00Z","endDate":"2024-12-04T14:33:00.000Z","url":"https://www.brighttalk.com/webcast/10519/623717","duration":"PT0H3M0S","location":{"@type":"VirtualLocation","name":"BrightTALK","url":"https://www.brighttalk.com/webcast/10519/623717","description":"Jay Bolden, Senior Director, Eli Lilly and Company Global Quality Laboratories. Presenting:\nAn Overview of Recent USP Bacterial Endotoxins Standards Development\n\nDr David Roesti, PhD. Microbiologist/Facilitator QA/QC at Novartis Pharma AG. Presenting:\nOverview and Future Plans of the USP Rapid Microbiological Methods Subcommittee\n\nVeronika Wills, Manager, Technical Services at Associates of Cape Cod, Inc\nPresenting: Early Implementation of Recombinant Cascade Reagent PyroSmart NextGen® in Line With USP <86>\n\nNicola Reid, Associate Director of Endotoxin Products, Charles River\nPresenting: A 3-Step Validation Blueprint for Recombinant Method Implementation\n\nLamin Jallow, Microbiology Technology Specialist at Merck KGaA\nPresenting: Early detection of microbial contaminants in cell-based products using the Milliflex® Rapid System\n\nFélix Montero-Julian, Scientific Director of Pharma Quality Control at bioMérieux\nPresenting: Implementation of BACT/ALERT® 3D in light of the USP <72> Chapter: Respiration-Based Microbiological Methods for the Detection of Contamination in Short-Life Products\n\nFollowed by a live Questions and Answers session.","image":"https://cdn.brighttalk.com/ams/california/images/communication/623717/image_1014649.jpg?width=640&height=360"},"image":"https://cdn.brighttalk.com/ams/california/images/communication/623717/image_1014649.jpg?width=640&height=360","performer":"Jay Bolden at Eli Lilly, Dr David Roesti, at Novartis Pharma AG, Veronika Wills at Associates of Cape Cod, Inc ,Nicola Reid at Charles River, Lamin Jallow at Merck KGaA and Félix Montero-Julian at bioMérieux","organizer":{"@type":"Organization","name":"BioPharma Webinars","description":"BioPharma Webinars aims to keep its global audience abreast of all developments in the areas of Drug Development, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality webinars, presented by the most respected people, working with companies in Pharmaceutical, Biopharmaceutical, Biologics and Biotech Industry.","url":"https://www.brighttalk.com/channel/10519"},"eventAttendanceMode":"OnlineEventAttendanceMode","eventStatus":"EventScheduled","aggregateRating":{"@type":"AggregateRating","bestRating":"5","worstRating":"1","ratingValue":0,"ratingCount":0}}</script><script async="" src="https://unpkg.com/date-time-format-timezone@latest/build/browserified/date-time-format-timezone-complete-min.js"></script><style type="text/css"> #cmp-banner { position: fixed; bottom: 0; left: 0; z-index: 1200; } @media (min-width: 960px) { #cmp-banner { bottom: 20px; left: 20px; } } #cmp-banner, #cmp-banner > div, #cmp-banner iframe { width: 300px; height: 275px; } #cmp-banner:empty { display: none; } </style><script type="text/javascript"> "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r<t;r++)n[r]=arguments[r];if(!n.length)return o;"setGdprApplies"===n[0]?n.length>3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); (function () { var e = false; var c = window; var t = document; function r() { if (!c.frames["__uspapiLocator"]) { if (t.body) { var a = t.body; var e = t.createElement("iframe"); e.style.cssText = "display:none"; e.name = "__uspapiLocator"; a.appendChild(e) } else { setTimeout(r, 5) } } } r(); function p() { var a = arguments; __uspapi.a = __uspapi.a || []; if (!a.length) { return __uspapi.a } else if (a[0] === "ping") { a[2]({ gdprAppliesGlobally: e, cmpLoaded: false }, true) } else { __uspapi.a.push([].slice.apply(a)) } } function l(t) { var r = typeof t.data === "string"; try { var a = r ? JSON.parse(t.data) : t.data; if (a.__cmpCall) { var n = a.__cmpCall; c.__uspapi(n.command, n.parameter, function (a, e) { var c = { __cmpReturn: { returnValue: a, success: e, callId: n.callId } }; t.source.postMessage(r ? JSON.stringify(c) : c, "*") }) } } catch (a) { } } if (typeof __uspapi !== "function") { c.__uspapi = p; __uspapi.msgHandler = l; c.addEventListener("message", l, false) } })(); window.__gpp_addFrame=function(e){if(!window.frames[e])if(document.body){var t=document.createElement("iframe");t.style.cssText="display:none",t.name=e,document.body.appendChild(t)}else window.setTimeout(window.__gpp_addFrame,10,e)},window.__gpp_stub=function(){var e=arguments;if(__gpp.queue=__gpp.queue||[],__gpp.events=__gpp.events||[],!e.length||1==e.length&&"queue"==e[0])return __gpp.queue;if(1==e.length&&"events"==e[0])return __gpp.events;var t=e[0],p=e.length>1?e[1]:null,s=e.length>2?e[2]:null;if("ping"===t)p({gppVersion:"1.1",cmpStatus:"stub",cmpDisplayStatus:"hidden",signalStatus:"not ready",supportedAPIs:["2:tcfeuv2","5:tcfcav1","6:uspv1","7:usnatv1","8:uscav1","9:usvav1","10:uscov1","11:usutv1","12:usctv1"],cmpId:0,sectionList:[],applicableSections:[],gppString:"",parsedSections:{}},!0);else if("addEventListener"===t){"lastId"in __gpp||(__gpp.lastId=0),__gpp.lastId++;var n=__gpp.lastId;__gpp.events.push({id:n,callback:p,parameter:s}),p({eventName:"listenerRegistered",listenerId:n,data:!0,pingData:{gppVersion:"1.1",cmpStatus:"stub",cmpDisplayStatus:"hidden",signalStatus:"not ready",supportedAPIs:["2:tcfeuv2","5:tcfcav1","6:uspv1","7:usnatv1","8:uscav1","9:usvav1","10:uscov1","11:usutv1","12:usctv1"],cmpId:0,sectionList:[],applicableSections:[],gppString:"",parsedSections:{}}},!0)}else if("removeEventListener"===t){for(var a=!1,i=0;i<__gpp.events.length;i++)if(__gpp.events[i].id==s){__gpp.events.splice(i,1),a=!0;break}p({eventName:"listenerRemoved",listenerId:s,data:a,pingData:{gppVersion:"1.1",cmpStatus:"stub",cmpDisplayStatus:"hidden",signalStatus:"not ready",supportedAPIs:["2:tcfeuv2","5:tcfcav1","6:uspv1","7:usnatv1","8:uscav1","9:usvav1","10:uscov1","11:usutv1","12:usctv1"],cmpId:0,sectionList:[],applicableSections:[],gppString:"",parsedSections:{}}},!0)}else"hasSection"===t?p(!1,!0):"getSection"===t||"getField"===t?p(null,!0):__gpp.queue.push([].slice.apply(e))},window.__gpp_msghandler=function(e){var t="string"==typeof e.data;try{var p=t?JSON.parse(e.data):e.data}catch(e){p=null}if("object"==typeof p&&null!==p&&"__gppCall"in p){var s=p.__gppCall;window.__gpp(s.command,(function(p,n){var a={__gppReturn:{returnValue:p,success:n,callId:s.callId}};e.source.postMessage(t?JSON.stringify(a):a,"*")}),"parameter"in s?s.parameter:null,"version"in s?s.version:"1.1")}},"__gpp"in window&&"function"==typeof window.__gpp||(window.__gpp=window.__gpp_stub,window.addEventListener("message",window.__gpp_msghandler,!1),window.__gpp_addFrame("__gppLocator")); window._sp_queue = []; window._sp_ = { config: { accountId: 370, baseEndpoint: 'https://cdn.privacy-mgmt.com', usnat: { includeUspApi: true }, gdpr: { }, events: { onMessageChoiceSelect: function (message_type, choice_id, choice_type_id) { // Code to make 'OK' and 'X' buttons work in the CPPA banner if(message_type === 'ccpa'){ console.log(choice_type_id); if(choice_type_id===11||choice_type_id===15){ document.getElementById("cmp-banner").style.display = "none"; } } }, onMessageReady: function() { console.log('[event] onMessageReady', arguments); }, onMessageChoiceError: function() { console.log('[event] onMessageChoiceError', arguments); }, onPrivacyManagerAction: function() { console.log('[event] onPrivacyManagerAction', arguments); }, onPMCancel: function() { console.log('[event] onPMCancel', arguments); }, onMessageReceiveData: function() { console.log('[event] onMessageReceiveData', arguments); }, onSPPMObjectReady: function() { console.log('[event] onSPPMObjectReady', arguments); }, onConsentReady: function (message_type, choice_type_id, choice_id, consentUUID, euconsent) { console.log('[event] onConsentReady', arguments); // Code to make 'OK' and 'X' buttons work in the CPPA banner if(message_type === 'usnat'){ if(document.getElementsByClassName('close-button')||document.getElementsByClassName('sp_choice_type_Accept')){ document.getElementById("cmp-banner").style.display = "none"; } } }, onError: function() { console.log('[event] onError', arguments); }, } } } </script><script src="https://cdn.privacy-mgmt.com/unified/wrapperMessagingWithoutDetection.js" async=""></script><meta name="next-head-count" content="31"/><script type="text/javascript"> window.dataLayer = window.dataLayer || []; function gtag() { dataLayer.push(arguments); } //default behavior gtag('consent', 'default', { 'ad_storage': 'granted', 'analytics_storage': 'granted', 'wait_for_update': 500 }); //behavior specific for end-users in the EEA gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'region': ['BE', 'BG', 'CZ', 'DK', 'CY', 'LV', 'LT', 'LU', 'ES', 'FR', 'HR', 'IT', 'PL', 'PT', 'RO', 'SI', 'HU', 'MT', 'NL', 'AT', 'IS', 'LI', 'NO', 'SK', 'FI', 'SE', 'DE', 'EE', 'IE', 'EL'], 'wait_for_update': 500 }); </script><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push( {'gtm.start': new Date().getTime(),event:'gtm.js'} );var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-NCXH7DF');</script><meta name="brighttalk-build"/><link rel="preload" href="https://assets.brighttalk.com/fonts/Roboto-Light.woff" as="font" type="font/woff" crossorigin="true"/><link rel="preload" href="https://assets.brighttalk.com/fonts/Roboto-Regular.woff" as="font" type="font/woff" crossorigin="true"/><link rel="preload" href="https://assets.brighttalk.com/fonts/Roboto-Bold.woff" as="font" type="font/woff" crossorigin="true"/><link rel="preload" href="https://assets.brighttalk.com/fonts/Roboto-Medium.woff" as="font" type="font/woff" crossorigin="true"/><script type="module" src="https://www.brighttalk.com/globalauth-helpercomponent/globalauth-helpercomponent.esm.js"></script><link rel="preload" href="/webcast/_next/static/css/f27ee2d0379f6a23.css" as="style"/><link rel="stylesheet" href="/webcast/_next/static/css/f27ee2d0379f6a23.css" data-n-g=""/><link rel="preload" href="/webcast/_next/static/css/96269a11e4525120.css" as="style"/><link rel="stylesheet" href="/webcast/_next/static/css/96269a11e4525120.css" data-n-p=""/><link rel="preload" href="/webcast/_next/static/css/ce5fea244d2c7257.css" as="style"/><link rel="stylesheet" href="/webcast/_next/static/css/ce5fea244d2c7257.css"/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/webcast/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script defer="" src="/webcast/_next/static/chunks/479.00bec7571fc3660a.js"></script><script src="/webcast/_next/static/chunks/webpack-b85caf12564da1cd.js" defer=""></script><script src="/webcast/_next/static/chunks/framework-aeb85a5e071ca0cb.js" defer=""></script><script src="/webcast/_next/static/chunks/main-5dfda2bd9643ffef.js" defer=""></script><script src="/webcast/_next/static/chunks/pages/_app-7ea91bd9cae06cc6.js" defer=""></script><script src="/webcast/_next/static/chunks/28455a0b-2cbae5c8e87fa36c.js" defer=""></script><script src="/webcast/_next/static/chunks/161-21e61a853b21e681.js" defer=""></script><script src="/webcast/_next/static/chunks/400-4e47201e7227ada6.js" defer=""></script><script src="/webcast/_next/static/chunks/9-a45af57e2b443b6a.js" defer=""></script><script src="/webcast/_next/static/chunks/pages/%5BchannelId%5D/%5BwebcastId%5D-5a1a962ff7432ecf.js" defer=""></script><script src="/webcast/_next/static/1079/_buildManifest.js" defer=""></script><script src="/webcast/_next/static/1079/_ssgManifest.js" defer=""></script><style id="__jsx-2556523208">.previewImg.jsx-2556523208{background:url(https://cdn.brighttalk.com/ams/california/images/communication/623717/image_1014649.jpg?width=640&height=360)center center no-repeat;-webkit-filter:blur(4rem)grayscale(30%);filter:blur(4rem)grayscale(30%);opacity:.17;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;width:100%;height:100%;-webkit-transform:scale(1.1);-moz-transform:scale(1.1);-ms-transform:scale(1.1);-o-transform:scale(1.1);transform:scale(1.1)}</style><style id="__jsx-81224b3dde91c69d">.global-footer.jsx-81224b3dde91c69d{background-color:rgb(92,92,92);min-height:394px}</style> <script>!function(e){var n="https://s.go-mpulse.net/boomerang/";if("False"=="True")e.BOOMR_config=e.BOOMR_config||{},e.BOOMR_config.PageParams=e.BOOMR_config.PageParams||{},e.BOOMR_config.PageParams.pci=!0,n="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="JVT9R-JD38W-BPCAY-8MYGM-PYXBG",function(){function e(){if(!o){var e=document.createElement("script");e.id="boomr-scr-as",e.src=window.BOOMR.url,e.async=!0,i.parentNode.appendChild(e),o=!0}}function t(e){o=!0;var n,t,a,r,d=document,O=window;if(window.BOOMR.snippetMethod=e?"if":"i",t=function(e,n){var t=d.createElement("script");t.id=n||"boomr-if-as",t.src=window.BOOMR.url,BOOMR_lstart=(new Date).getTime(),e=e||d.body,e.appendChild(t)},!window.addEventListener&&window.attachEvent&&navigator.userAgent.match(/MSIE [67]\./))return window.BOOMR.snippetMethod="s",void t(i.parentNode,"boomr-async");a=document.createElement("IFRAME"),a.src="about:blank",a.title="",a.role="presentation",a.loading="eager",r=(a.frameElement||a).style,r.width=0,r.height=0,r.border=0,r.display="none",i.parentNode.appendChild(a);try{O=a.contentWindow,d=O.document.open()}catch(_){n=document.domain,a.src="javascript:var d=document.open();d.domain='"+n+"';void(0);",O=a.contentWindow,d=O.document.open()}if(n)d._boomrl=function(){this.domain=n,t()},d.write("<bo"+"dy onload='document._boomrl();'>");else if(O._boomrl=function(){t()},O.addEventListener)O.addEventListener("load",O._boomrl,!1);else if(O.attachEvent)O.attachEvent("onload",O._boomrl);d.close()}function a(e){window.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!window.BOOMR||!window.BOOMR.version&&!window.BOOMR.snippetExecuted){window.BOOMR=window.BOOMR||{},window.BOOMR.snippetStart=(new Date).getTime(),window.BOOMR.snippetExecuted=!0,window.BOOMR.snippetVersion=12,window.BOOMR.url=n+"JVT9R-JD38W-BPCAY-8MYGM-PYXBG";var i=document.currentScript||document.getElementsByTagName("script")[0],o=!1,r=document.createElement("link");if(r.relList&&"function"==typeof r.relList.supports&&r.relList.supports("preload")&&"as"in r)window.BOOMR.snippetMethod="p",r.href=window.BOOMR.url,r.rel="preload",r.as="script",r.addEventListener("load",e),r.addEventListener("error",function(){t(!0)}),setTimeout(function(){if(!o)t(!0)},3e3),BOOMR_lstart=(new Date).getTime(),i.parentNode.appendChild(r);else t(!1);if(window.addEventListener)window.addEventListener("load",a,!1);else if(window.attachEvent)window.attachEvent("onload",a)}}(),"".length>0)if(e&&"performance"in e&&e.performance&&"function"==typeof e.performance.setResourceTimingBufferSize)e.performance.setResourceTimingBufferSize();!function(){if(BOOMR=e.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var n=""=="true"?1:0,t="",a="bdpnbeqx3ntrcz2gvhta-f-5b8fbc288-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,o={"ak.v":"39","ak.cp":"87120","ak.ai":parseInt("390532",10),"ak.ol":"0","ak.cr":16,"ak.ipv":4,"ak.proto":"http/1.1","ak.rid":"1675ada7","ak.r":30210,"ak.a2":n,"ak.m":"b","ak.n":"essl","ak.bpcip":"8.222.208.0","ak.cport":50620,"ak.gh":"23.50.117.150","ak.quicv":"","ak.tlsv":"tls1.2","ak.0rtt":"","ak.0rtt.ed":"","ak.csrc":"-","ak.acc":"reno","ak.t":"1732684262","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==4GuinRjyIhKWbWoWyFYkDDpAqnAcVqq0QQRb7FfjTPURgnkJRzmyGsU256fSINE88XIK74iJ+wkoWVND8QUkOoj5TL+9+5fP5JC0nqwpqzhghAabZ3LeKKU25oSNLXZD4c7VVG0oyTSnWPV45KKdUC5SaGhivvzjttXySe/kSEGoHByqaJIhU4b3GHu6irgmQJF3l4jDkzCOgCr0Sf2N896ymJcc6+upMi+tW3Z/c4r4Dxjp3roCN8JVhoTqmTv2UfZKm7gfZE6jXupoF1/TmCxZe6Ludd7q3n3lYXRCWKR2KBE+ApVjTNQ4db+psBbnqTzP7vo2Rwp4DnabaA6piCjq1+UJgoVD3xWT6K25NAKzQxouUfAgnFla4aMPE7r66PNJj4kJF0c3oOgvux1G/uvvNTOR6T+9ChvkBSCvsVk=","ak.pv":"286","ak.dpoabenc":"","ak.tf":i};if(""!==t)o["ak.ruds"]=t;var r={i:!1,av:function(n){var t="http.initiator";if(n&&(!n[t]||"spa_hard"===n[t]))o["ak.feo"]=void 0!==e.aFeoApplied?1:0,BOOMR.addVar(o)},rv:function(){var e=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","ak.m","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.0rtt.ed","ak.r","ak.acc","ak.t","ak.tf"];BOOMR.removeVar(e)}};BOOMR.plugins.AK={akVars:o,akDNSPreFetchDomain:a,init:function(){if(!r.i){var e=BOOMR.subscribe;e("before_beacon",r.av,null,null),e("onbeacon",r.rv,null,null),r.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NCXH7DF" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><div id="__next"> <div class="PageContent_app__Tw3yY"><div id="cmp-banner"></div><div class="ClientHeader_ClientHeader__Yhcmr ClientHeader_ClientHeader-basics__Tkt9O" data-preview-img="https://cdn.brighttalk.com/ams/california/images/communication/623717/image_1014649.jpg?width=640&height=360" aria-hidden="true" data-bdd="client-header"><div class="jsx-2556523208 previewImg"></div><div class="ClientHeader_ClientHeader--Gradient___ql1Q ClientHeader_ClientHeader-basics__Tkt9O"></div></div><span><div class="global-header"><link rel="modulepreload" href="https://www.brighttalk.com/webcomponent/dist/brighttalk-web-components/brighttalk-web-components.esm.js"/><style> .global-header { background-color: white; min-height: 106px; margin-bottom: 30px; } </style></div></span><div class="Container_Container__cJtME PageContent_Player-Content__cuHLP"><main class="PageContent_Player-Content-Main__dT2hM" id="bt-player-content-main"><section class="Section_Section30__FyFjI"><h1 data-bdd="player-webcast-title">Current Status and Overview of the RMM and Endotoxin Microbiology USP Chapters under Development</h1><section class="Section_Section10__MY7SZ WebcastHeader_WebcastHeader-Subheader-Container__eoyOs" data-bdd="player-webcast-content"><div class="WebcastHeader_WebcastHeader-Subheader__2hOd6"><time class="WebcastHeader_WebcastHeader-Duration__Ojp_n" data-bdd="player-webcast-duration" dateTime="180m"><span>Duration: </span><span>180 mins</span></time></div><div class="WebcastHeader_WebcastHeader-Extra__mYsCW"></div></section><section class="Section_Section40__iljNL DefaultWebcastContent_DefaultWebcastContent--pad-right__m0r9W"><div class="PlayerPlaceholder_outer__erL98" data-bdd="player-placeholder"><div class="PlayerPlaceholder_PlayerPlaceholder__E0yEP" id="default-placeholder"><div style="--aspect-ratio:(16/9)" data-bdd="thumbnail-container" class="Thumbnail_thumbnail__nQlEr Thumbnail_thumbnail--small__tLn5m PlayerPlaceholder_PlayerPlaceholder-ThumbnailIE__p2acC PlayerPlaceholder_PlayerPlaceholder--max-height__ylfXH PlayerPlaceholder_PlayerNoCrusor__AAgzp"><img src="https://cdn.brighttalk.com/ams/california/images/communication/623717/image_1014649.jpg?width=640&height=360" alt="" class="Thumbnail_thumbnail-img__Odh48" data-bdd="player-placeholder-thumbnail" width="647" height="364"/></div></div></div></section><section data-bdd="player-details"><article class="DefaultWebcastContent_DefaultWebcastContent-article__NVTL1"><h2 class="DefaultWebcastContent_DefaultWebcastContent-Header3__AZoDj"><div data-bdd="player-channel-logo" class="Thumbnail_thumbnail__nQlEr Thumbnail_thumbnail--borderless__hCROE Thumbnail_thumbnail--bg-transparent__YK03i DefaultWebcastContent_DefaultWebcastContent-ChannelLogo__PbB1y"><img src="https://cdn.brighttalk.com/ams/california/images/channel/10519/image_873770.jpg?width=300&height=300" alt="Logo" class="Thumbnail_thumbnail-img__Odh48" width="40" height="40"/></div><span>Presented by</span></h2><p class="DefaultWebcastContent_DefaultWebcastContent-P__e8prc" data-bdd="player-presenter">Jay Bolden at Eli Lilly, Dr David Roesti, at Novartis Pharma AG, Veronika Wills at Associates of Cape Cod, Inc ,Nicola Reid at Charles River, Lamin Jallow at Merck KGaA and Félix Montero-Julian at bioMérieux</p></article><article><h2 class="DefaultWebcastContent_DefaultWebcastContent-Header3__AZoDj">About this talk</h2><div class="DefaultWebcastContent_DefaultWebcastContent-P__e8prc" data-bdd="player-body"><div class="Markdown_Markdown__kIRZG">Jay Bolden, Senior Director, Eli Lilly and Company Global Quality Laboratories. Presenting: An Overview of Recent USP Bacterial Endotoxins Standards Development Dr David Roesti, PhD. Microbiologist/Facilitator QA/QC at Novartis Pharma AG. Presenting: Overview and Future Plans of the USP Rapid Microbiological Methods Subcommittee Veronika Wills, Manager, Technical Services at Associates of Cape Cod, Inc Presenting: Early Implementation of Recombinant Cascade Reagent PyroSmart NextGen® in Line With USP <86> Nicola Reid, Associate Director of Endotoxin Products, Charles River Presenting: A 3-Step Validation Blueprint for Recombinant Method Implementation Lamin Jallow, Microbiology Technology Specialist at Merck KGaA Presenting: Early detection of microbial contaminants in cell-based products using the Milliflex® Rapid System Félix Montero-Julian, Scientific Director of Pharma Quality Control at bioMérieux Presenting: Implementation of BACT/ALERT® 3D in light of the USP <72> Chapter: Respiration-Based Microbiological Methods for the Detection of Contamination in Short-Life Products Followed by a live Questions and Answers session.</div></div></article></section></section><section class="Section_Section30__FyFjI SocialButtons_SocialButton__Khmr6" data-bdd="social-buttons"><button data-bdd="social-buttons-linkedin" class="react-share__ShareButton SocialButtons_SocialButton-Button-container__Y2hbD SocialButtons_SocialButton--margin-right__jY5Gd" style="background-color:transparent;border:none;padding:0;font:inherit;color:inherit;cursor:pointer"><div class="SocialButtons_SocialButton-Button__EQIlf SocialButtons_SocialButton-LinkedIn__3t34y globalStyle_hnm___IQTm"><div class="Center_Center-Component__avfAw"><div class="TextWithIcon_TextWithIcon__IAwM1 TextWithIcon_TextWithIcon--small__QcS4i globalStyle_hnl__lyhgl TextWithIcon_TextWithIcon--concise__F7v2W SocialButtons_SocialButton-TextWithIcon__dM6Uh" data-bdd="social-buttons-icon-linkedin"><div class="TextWithIcon_TextWithIcon-Icon__d57WI TextWithIcon_TextWithIcon-Icon--small__S1_da" data-overlay="text-with-icon-noclick" data-bdd="social-buttons-icon-linkedin-click"><svg aria-hidden="true" focusable="false" data-prefix="fab" data-icon="linkedin-in" class="svg-inline--fa fa-linkedin-in getColorClass_text-white__FAWAD" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" data-bdd="item-linkedIn"><path fill="currentColor" d="M100.28 448H7.4V148.9h92.88zM53.79 108.1C24.09 108.1 0 83.5 0 53.8a53.79 53.79 0 0 1 107.58 0c0 29.7-24.1 54.3-53.79 54.3zM447.9 448h-92.68V302.4c0-34.7-.7-79.2-48.29-79.2-48.29 0-55.69 37.7-55.69 76.7V448h-92.78V148.9h89.08v40.8h1.3c12.4-23.5 42.69-48.3 87.88-48.3 94 0 111.28 61.9 111.28 142.3V448z"></path></svg></div><span class="TextWithIcon_TextWithIcon--text__ypZJl">Share</span></div></div></div></button><button data-bdd="social-buttons-twitter" class="react-share__ShareButton SocialButtons_SocialButton-Button-container__Y2hbD SocialButtons_SocialButton--margin-right__jY5Gd" style="background-color:transparent;border:none;padding:0;font:inherit;color:inherit;cursor:pointer"><div class="SocialButtons_SocialButton-Button__EQIlf SocialButtons_SocialButton-Twitter__vuC1V globalStyle_hnm___IQTm"><div class="Center_Center-Component__avfAw"><div class="TextWithIcon_TextWithIcon__IAwM1 TextWithIcon_TextWithIcon--small__QcS4i globalStyle_hnl__lyhgl TextWithIcon_TextWithIcon--concise__F7v2W SocialButtons_SocialButton-TextWithIcon__dM6Uh" data-bdd="social-buttons-icon-twitter"><div class="TextWithIcon_TextWithIcon-Icon__d57WI TextWithIcon_TextWithIcon-Icon--small__S1_da" data-overlay="text-with-icon-noclick" data-bdd="social-buttons-icon-twitter-click"><svg aria-hidden="true" focusable="false" data-prefix="fab" data-icon="x-twitter" class="svg-inline--fa fa-x-twitter getColorClass_text-white__FAWAD" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" data-bdd="item-xTwitter"><path fill="currentColor" d="M389.2 48h70.6L305.6 224.2 487 464H345L233.7 318.6 106.5 464H35.8L200.7 275.5 26.8 48H172.4L272.9 180.9 389.2 48zM364.4 421.8h39.1L151.1 88h-42L364.4 421.8z"></path></svg></div><span class="TextWithIcon_TextWithIcon--text__ypZJl">Post</span></div></div></div></button><button data-bdd="social-buttons-facebook" class="react-share__ShareButton SocialButtons_SocialButton-Button-container__Y2hbD SocialButtons_SocialButton--margin-right__jY5Gd" style="background-color:transparent;border:none;padding:0;font:inherit;color:inherit;cursor:pointer"><div class="SocialButtons_SocialButton-Button__EQIlf SocialButtons_SocialButton-Facebook__WioB_ globalStyle_hnm___IQTm"><div class="Center_Center-Component__avfAw"><div class="TextWithIcon_TextWithIcon__IAwM1 TextWithIcon_TextWithIcon--small__QcS4i globalStyle_hnl__lyhgl TextWithIcon_TextWithIcon--concise__F7v2W SocialButtons_SocialButton-TextWithIcon__dM6Uh" data-bdd="social-buttons-icon-facebook"><div class="TextWithIcon_TextWithIcon-Icon__d57WI TextWithIcon_TextWithIcon-Icon--small__S1_da" data-overlay="text-with-icon-noclick" data-bdd="social-buttons-icon-facebook-click"><svg aria-hidden="true" focusable="false" data-prefix="fab" data-icon="facebook-f" class="svg-inline--fa fa-facebook-f getColorClass_text-white__FAWAD" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 320 512" data-bdd="item-facebook"><path fill="currentColor" d="M80 299.3V512H196V299.3h86.5l18-97.8H196V166.9c0-51.7 20.3-71.5 72.7-71.5c16.3 0 29.4 .4 37 1.2V7.9C291.4 4 256.4 0 236.2 0C129.3 0 80 50.5 80 159.4v42.1H14v97.8H80z"></path></svg></div><span class="TextWithIcon_TextWithIcon--text__ypZJl">Share</span></div></div></div></button><div><button class="SocialButtons_SocialButton-Button__EQIlf SocialButtons_SocialButton-Linkshare__ATipv globalStyle_hnm___IQTm" data-bdd="social-buttons-linkshare"><div class="Center_Center-Component__avfAw"><div class="TextWithIcon_TextWithIcon__IAwM1 TextWithIcon_TextWithIcon--small__QcS4i globalStyle_hnl__lyhgl TextWithIcon_TextWithIcon--concise__F7v2W SocialButtons_SocialButton-TextWithIcon__dM6Uh" data-bdd="social-buttons-icon-linkshare"><div class="TextWithIcon_TextWithIcon-Icon__d57WI TextWithIcon_TextWithIcon-Icon--small__S1_da" data-overlay="text-with-icon-noclick" data-bdd="social-buttons-icon-linkshare-click"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="link" class="svg-inline--fa fa-link getColorClass_text-white__FAWAD" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 640 512" data-bdd="item-link"><path fill="currentColor" d="M579.8 267.7c56.5-56.5 56.5-148 0-204.5c-50-50-128.8-56.5-186.3-15.4l-1.6 1.1c-14.4 10.3-17.7 30.3-7.4 44.6s30.3 17.7 44.6 7.4l1.6-1.1c32.1-22.9 76-19.3 103.8 8.6c31.5 31.5 31.5 82.5 0 114L422.3 334.8c-31.5 31.5-82.5 31.5-114 0c-27.9-27.9-31.5-71.8-8.6-103.8l1.1-1.6c10.3-14.4 6.9-34.4-7.4-44.6s-34.4-6.9-44.6 7.4l-1.1 1.6C206.5 251.2 213 330 263 380c56.5 56.5 148 56.5 204.5 0L579.8 267.7zM60.2 244.3c-56.5 56.5-56.5 148 0 204.5c50 50 128.8 56.5 186.3 15.4l1.6-1.1c14.4-10.3 17.7-30.3 7.4-44.6s-30.3-17.7-44.6-7.4l-1.6 1.1c-32.1 22.9-76 19.3-103.8-8.6C74 372 74 321 105.5 289.5L217.7 177.2c31.5-31.5 82.5-31.5 114 0c27.9 27.9 31.5 71.8 8.6 103.9l-1.1 1.6c-10.3 14.4-6.9 34.4 7.4 44.6s34.4 6.9 44.6-7.4l1.1-1.6C433.5 260.8 427 182 377 132c-56.5-56.5-148-56.5-204.5 0L60.2 244.3z"></path></svg></div><span class="TextWithIcon_TextWithIcon--text__ypZJl">Link</span></div></div></button><div class="LinksharePopup_LinksharePopup__rsmX8 LinksharePopup_LinksharePopup-Mobile-Tab-View__8gjE6" aria-hidden="true" data-bdd="linkshare-popup">Copied!<div class="LinksharePopup_LinksharePopup-Footer__52NUr" data-bdd="linkshare-popup-footer"></div></div></div></section><section class="Section_Section30__FyFjI RelatedTopics_RelatedTopics__J973v" data-bdd="related-topic"><div class="RelatedTopics_RelatedTopics-Label__Qc2fT" data-bdd="related-topic-header">Related topics:</div><div class="RelatedTopics_RelatedTopics-Items__VQabW" data-bdd="related-topic-items"><a href="https://www.brighttalk.com/topic/recombinant-reagents" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-0-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-0-text">Recombinant reagents</div></a><a href="https://www.brighttalk.com/topic/factor-c-protein" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-1-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-1-text">Factor C protein</div></a><a href="https://www.brighttalk.com/topic/usp" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-2-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-2-text">USP</div></a><a href="https://www.brighttalk.com/topic/microbiology" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-3-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-3-text">Microbiology</div></a><a href="https://www.brighttalk.com/topic/rapid-microbial-methods" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-4-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-4-text">Rapid microbial methods</div></a><a href="https://www.brighttalk.com/topic/limulus-amebocyte-lysate" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-5-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-5-text">Limulus amebocyte lysate</div></a><a href="https://www.brighttalk.com/topic/lal" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-6-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-6-text">LAL</div></a><a href="https://www.brighttalk.com/topic/bacterial-endotoxin-tests" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-7-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-7-text">Bacterial Endotoxin Tests</div></a></div></section><section class="Section_Section20__bSvI1" data-bdd="channel-info"><div class="SectionHeading_SectionHeading__NkeuR"><h3 data-bdd="channel-info-header" class="">More from this channel</h3></div><div class="ChannelInfo_ChannelInfo__oTF6i"><div class="ChannelInfo_ChannelInfo-Header__Fx7LJ"><a href="https://www.brighttalk.com/channel/10519/" title="Visit BioPharma Webinars's channel" class="ChannelInfo_ChannelInfo-Link__PqzoP globalStyle_hnm___IQTm" data-bdd="channel-info-channel-link"><span class="ChannelInfo_ChannelInfo-Logo__iCERc" data-bdd="channel-info-logo"><div data-bdd="thumbnail-container" class="Thumbnail_thumbnail__nQlEr Thumbnail_thumbnail--borderless__hCROE Thumbnail_thumbnail--bg-transparent__YK03i"><img src="https://cdn.brighttalk.com/ams/california/images/channel/10519/image_873770.jpg?width=300&height=300" alt="BioPharma Webinars logo" class="Thumbnail_thumbnail-img__Odh48" width="40" height="40"/></div></span><span class="ChannelInfo_ChannelInfo-Name__36UR1" data-bdd="channel-info-name">BioPharma Webinars</span></a></div><div class="ChannelInfo_ChannelInfo-Body__Vnmoe"><div class="ChannelInfo_ChannelInfo-Summary__eNUvy"><div class="ChannelInfo_ChannelInfo-SummaryItem--margin__5IC63"><span class="ChannelInfo_ChannelInfo-SummaryIcon__vypMF"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="calendar" class="svg-inline--fa fa-calendar getColorClass_text-secondary__5o8tz ChannelInfo_ChannelInfo--grey__D2sZ4" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" data-bdd="item-calendarSolid"><path fill="currentColor" d="M96 32V64H48C21.5 64 0 85.5 0 112v48H448V112c0-26.5-21.5-48-48-48H352V32c0-17.7-14.3-32-32-32s-32 14.3-32 32V64H160V32c0-17.7-14.3-32-32-32S96 14.3 96 32zM448 192H0V464c0 26.5 21.5 48 48 48H400c26.5 0 48-21.5 48-48V192z"></path></svg></span><span class="ChannelInfo_ChannelInfo-SummaryText__pbg3I" data-bdd="channel-info-upcoming">Upcoming talks (<b>8</b>)</span></div><div class="ChannelInfo_ChannelInfo-SummaryItem--margin__5IC63"><span class="ChannelInfo_ChannelInfo-SummaryIcon__vypMF"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="play" class="svg-inline--fa fa-play getColorClass_text-secondary__5o8tz ChannelInfo_ChannelInfo--grey__D2sZ4" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512" data-bdd="item-play"><path fill="currentColor" d="M73 39c-14.8-9.1-33.4-9.4-48.5-.9S0 62.6 0 80V432c0 17.4 9.4 33.4 24.5 41.9s33.7 8.1 48.5-.9L361 297c14.3-8.7 23-24.2 23-41s-8.7-32.2-23-41L73 39z"></path></svg></span><span class="ChannelInfo_ChannelInfo-SummaryText__pbg3I" data-bdd="channel-info-ondemand">On-demand talks (<b>415</b>)</span></div><div><span class="ChannelInfo_ChannelInfo-SummaryIcon__vypMF"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="users" class="svg-inline--fa fa-users getColorClass_text-secondary__5o8tz ChannelInfo_ChannelInfo--grey__D2sZ4" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 640 512" data-bdd="item-users"><path fill="currentColor" d="M144 0a80 80 0 1 1 0 160A80 80 0 1 1 144 0zM512 0a80 80 0 1 1 0 160A80 80 0 1 1 512 0zM0 298.7C0 239.8 47.8 192 106.7 192h42.7c15.9 0 31 3.5 44.6 9.7c-1.3 7.2-1.9 14.7-1.9 22.3c0 38.2 16.8 72.5 43.3 96c-.2 0-.4 0-.7 0H21.3C9.6 320 0 310.4 0 298.7zM405.3 320c-.2 0-.4 0-.7 0c26.6-23.5 43.3-57.8 43.3-96c0-7.6-.7-15-1.9-22.3c13.6-6.3 28.7-9.7 44.6-9.7h42.7C592.2 192 640 239.8 640 298.7c0 11.8-9.6 21.3-21.3 21.3H405.3zM224 224a96 96 0 1 1 192 0 96 96 0 1 1 -192 0zM128 485.3C128 411.7 187.7 352 261.3 352H378.7C452.3 352 512 411.7 512 485.3c0 14.7-11.9 26.7-26.7 26.7H154.7c-14.7 0-26.7-11.9-26.7-26.7z"></path></svg></span><span class="ChannelInfo_ChannelInfo-SummaryText__pbg3I" data-bdd="channel-info-subscribers">Subscribers (<b>38786</b>)</span></div></div><div class="ChannelInfo_ChannelInfo-Description__x_HRU" data-bdd="channel-info-body"><span data-bdd="channel-info-description" width="0"><span></span><span>BioPharma Webinars aims to keep its global audience abreast of all developments in the areas of Drug Development, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality webinars, presented by the most respected people, working with companies in Pharmaceutical, Biopharmaceutical, Biologics and Biotech Industry.</span><span style="position:fixed;visibility:hidden;top:0;left:0">…</span></span></div></div></div></section></main><aside class="PageContent_Player-Content-Aside__ejqAg"><div class="SidePanel_form-wrapper__XAlVE"><div class="SidePanel_globalauth-wrapper__fRQUj"><div class="SidePanel_spinner-wrapper__vIlwe"><div class="GlobalAuthSkeleton_wrapper__bWg5s"><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_heading__oXy64"></div><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_input__q43DK"></div><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_button__Ji96E"></div><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_text___CPXT"></div><div class="GlobalAuthSkeleton_privacy-text__U75_Y"><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_text___CPXT"></div><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_text___CPXT"></div><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_text___CPXT"></div><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_text___CPXT"></div><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_text-1__a9eLg"></div></div></div></div></div></div></aside></div><div class="jsx-81224b3dde91c69d global-footer"><portal-footer env="prod" className="jsx-81224b3dde91c69d"></portal-footer></div></div> </div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"channelId":"10519","webcastId":"623717","channel":{"id":10519,"statistics":{"upcomingCommunications":"8","liveCommunications":"0","recordedCommunications":"415","subscribers":"38786","viewedSeconds":"230016777"},"channelName":"BioPharma Webinars","channelUrl":"https://www.brighttalk.com/channel/10519","channelDescription":"BioPharma Webinars aims to keep its global audience abreast of all developments in the areas of Drug Development, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality webinars, presented by the most respected people, working with companies in Pharmaceutical, Biopharmaceutical, Biologics and Biotech Industry.","visibility":"included","channelImg":"https://cdn.brighttalk.com/ams/california/images/channel/10519/image_873770.jpg?width=300\u0026height=300","locale":"en-US","showAttendees":false,"showShare":true,"showSocial":true},"webcast":{"id":623717,"channel":{"id":10519},"title":"Current Status and Overview of the RMM and Endotoxin Microbiology USP Chapters under Development","description":"Jay Bolden, Senior Director, Eli Lilly and Company Global Quality Laboratories. Presenting:\nAn Overview of Recent USP Bacterial Endotoxins Standards Development\n\nDr David Roesti, PhD. Microbiologist/Facilitator QA/QC at Novartis Pharma AG. Presenting:\nOverview and Future Plans of the USP Rapid Microbiological Methods Subcommittee\n\nVeronika Wills, Manager, Technical Services at Associates of Cape Cod, Inc\nPresenting: Early Implementation of Recombinant Cascade Reagent PyroSmart NextGen® in Line With USP \u003c86\u003e\n\nNicola Reid, Associate Director of Endotoxin Products, Charles River\nPresenting: A 3-Step Validation Blueprint for Recombinant Method Implementation\n\nLamin Jallow, Microbiology Technology Specialist at Merck KGaA\nPresenting: Early detection of microbial contaminants in cell-based products using the Milliflex® Rapid System\n\nFélix Montero-Julian, Scientific Director of Pharma Quality Control at bioMérieux\nPresenting: Implementation of BACT/ALERT® 3D in light of the USP \u003c72\u003e Chapter: Respiration-Based Microbiological Methods for the Detection of Contamination in Short-Life Products\n\nFollowed by a live Questions and Answers session.","presenter":"Jay Bolden at Eli Lilly, Dr David Roesti, at Novartis Pharma AG, Veronika Wills at Associates of Cape Cod, Inc ,Nicola Reid at Charles River, Lamin Jallow at Merck KGaA and Félix Montero-Julian at bioMérieux","duration":180,"keywords":"Recombinant reagents, Factor C protein, USP, Microbiology, Rapid microbial methods, Limulus amebocyte lysate, LAL, Bacterial Endotoxin Tests","start":"2024-12-04T14:30:00Z","entryTime":"2024-12-04T14:25:00Z","end":"","status":"upcoming","timeZone":"America/New_York","url":"https://www.brighttalk.com/webcast/10519/623717","isGigCancelled":false,"previewImg":"https://cdn.brighttalk.com/ams/california/images/communication/623717/image_1014649.jpg?width=640\u0026height=360","topics":[{"title":"Recombinant reagents","url":"https://www.brighttalk.com/topic/recombinant-reagents"},{"title":"Factor C protein","url":"https://www.brighttalk.com/topic/factor-c-protein"},{"title":"USP","url":"https://www.brighttalk.com/topic/usp"},{"title":"Microbiology","url":"https://www.brighttalk.com/topic/microbiology"},{"title":"Rapid microbial methods","url":"https://www.brighttalk.com/topic/rapid-microbial-methods"},{"title":"Limulus amebocyte lysate","url":"https://www.brighttalk.com/topic/limulus-amebocyte-lysate"},{"title":"LAL","url":"https://www.brighttalk.com/topic/lal"},{"title":"Bacterial Endotoxin Tests","url":"https://www.brighttalk.com/topic/bacterial-endotoxin-tests"}],"pageState":"scheduled","visibility":"public","syndication":null,"rating":0,"ratingCount":0},"summit":{"eventCount":0,"img":"","link":"","live":[],"onDemand":[],"showTracks":false,"summitDate":"","title":"","tracks":[],"upcoming":[],"target":"","type":""},"webcastCommunities":{"communities":[{"id":230,"title":"Healthcare","description":"Healthcare","alias":"healthcare","entryCount":0,"childCount":3,"enabled":true,"primary":false,"children":[{"id":19,"title":"Medical Research","description":"The medical research community on BrightTALK brings together medical and research professionals. Find relevant webinars on medical research, laboratory science, continuing medical education and more presented by recognized medical researchers. Join the conversation by participating in live webinars and round table discussions on the latest in medical devices, medical research practices and trends in the healthcare industry.","alias":"medical-research","entryCount":2615,"childCount":0,"enabled":true,"primary":false},{"id":77,"title":"Health IT","description":"Thousands of healthcare IT professionals compose the health IT community on BrightTALK. Learn alongside them with relevant webinars on healthcare IT compliance, big data in healthcare and IT solutions for healthcare organizations. Join the conversation by asking questions and engaging with other participants during live webinars and organized discussions.","alias":"health-it","entryCount":8750,"childCount":0,"enabled":true,"primary":false},{"id":205,"title":"Life Sciences","description":"Get powerful life science insights from influential experts. Connect with thought leaders and colleagues to get the most up-to-date knowledge on strategies and initiatives to accelerate the transformation of U.S. and global health care from a volume- to value-based marketplace.","alias":"life-sciences","entryCount":2834,"childCount":0,"enabled":true,"primary":true}]},{"id":6,"title":"Research and Development","description":"The research and development community on BrightTALK brings together leading professionals in healthcare, technology and manufacturing to present on current topics in their fields. From big data in healthcare to online forensics training and medical research practices, the community is an exceptional resource for those looking to expand their knowledge. Be part of the conversation by joining the community and participating in interactive live webinars.","alias":"research-development","entryCount":32093,"childCount":1,"enabled":true,"primary":false,"children":[{"id":139,"title":"Forensic Science","description":"Join the BrightTALK forensic science community for access to online forensics training from respected professionals in the field. Study forensic science online to learn necessary skills for trace evidence in forensics, liquid and gas chromatography and sample preparation. You can also attend live webinars to interact with forensic scientists and have your questions answered.","alias":"forensic-science","entryCount":679,"childCount":0,"enabled":true,"primary":false}]}]},"channelFeed":[{"date":"2025-09-04T14:00:00.000Z","id":627722,"channelId":10519,"thumbnail":{"alt":"Analytical Assessment of Leachables in Biological Drug Products: FDA Approach in Reviewing Information","url":"https://cdn.brighttalk.com/ams/california/images/communication/627722/image_1013120.jpg?width=640\u0026height=360"},"title":"Analytical Assessment of Leachables in Biological Drug Products: FDA Approach in Reviewing Information","description":"Andrey Sarafanov; PhD., Principal Investigator at U.S. FDA, Center for Biologics Evaluation and Research\nPresenting: Analytical Assessment of Leachables in Biological Drug Products: FDA Approach in Reviewing Information","link":"https://www.brighttalk.com/webcast/10519/627722","status":"upcoming","duration":7200},{"date":"2025-03-27T14:00:00.000Z","id":629429,"channelId":10519,"thumbnail":{"alt":"CMC Progression from Early to Late Phase – Practical Considerations for Gene Therapy","url":"https://cdn.brighttalk.com/ams/california/images/communication/629429/image_1010978.jpg?width=640\u0026height=360"},"title":"CMC Progression from Early to Late Phase – Practical Considerations for Gene Therapy","description":"The principles for developing traditional biologics are well established, but do not always translate well to cell and gene therapy products. Creative yet practical adaptations are necessary to advance gene therapy programs toward licensure. During this presentation we will explore three key areas where practical adaptations are required:\n\nBuilding toward the commercial process: change control and managing product evolution for non-traditional development pathways, comparability challenges, and regulatory expectations\n\nMaturation of analytics – the level of product understanding expected as programs advance, method advancement from early to late phase, ensuring repeatability and robustness in method performance\n\nFinding the right partners – finding the right match in terms complementary capabilities, technical performance, phase-appropriate GMP compliance and client service infrastructure","link":"https://www.brighttalk.com/webcast/10519/629429","status":"upcoming","duration":7200},{"date":"2025-03-05T15:00:00.000Z","id":628817,"channelId":10519,"thumbnail":{"alt":"Big Data Strategies for Cell Therapy Manufacturing","url":"https://cdn.brighttalk.com/ams/california/images/communication/628817/image_1009881.jpg?width=640\u0026height=360"},"title":"Big Data Strategies for Cell Therapy Manufacturing","description":"Cell and gene therapy (CGT) is particularly well-suited for the application of big data analytics. Although our understanding of these complex therapies remains limited, CGT manufacturing processes and analytical methods generate substantial datasets that can be analyzed using artificial intelligence and machine learning algorithms. These advanced computational tools are instrumental in identifying critical characteristics of novel CGT products, optimizing manufacturing and analytical methods, and defining predictive biomarkers, among other applications. This presentation will discuss the role of big data in the development and manufacturing of CGT products and will explore opportunities for crowdsourcing data in the precompetitive space.","link":"https://www.brighttalk.com/webcast/10519/628817","status":"upcoming","duration":7200},{"date":"2025-02-27T15:00:00.000Z","id":629083,"channelId":10519,"thumbnail":{"alt":"Navigating the Complexities of mRNA Therapies Analysis: Challenges, Techniques, and Quality Assessment Strategies","url":"https://cdn.brighttalk.com/ams/california/images/communication/629083/image_1010550.jpg?width=640\u0026height=360"},"title":"Navigating the Complexities of mRNA Therapies Analysis: Challenges, Techniques, and Quality Assessment Strategies","description":"The approval and widespread adoption of mRNA vaccines have revolutionized the field of immunization, offering rapid and scalable solutions to combat infectious diseases. This success has spurred significant research into using mRNA for other therapies, including cell therapies, protein production, genome editing and protein replacement. Ensuring the quality and safety of mRNAs in these therapies is crucial, requiring detailed impurity profiling and advanced analytical techniques. Incorporating mRNA into drug products presents significant manufacturing and analytical challenges, particularly in maintaining the integrity of mRNA drug substances and drug products. Rigorous release and stability testing are essential to ensuring these therapeutic products remain effective and safe throughout their lifecycle.\n\nImpurity profiling is an essential part of analytical characterization for mRNA-based products. During production, both process and product impurities can arise, such as truncated mRNA fragments, double-stranded RNA (dsRNA), and residual DNA from the plasmid template. These impurities can potentially impact the drug’s performance or trigger unintended immune responses. This presentation explores the types of impurities commonly found in mRNA-based products and the advanced analytical methods used to analyze them. We will also discuss the challenges faced, potential solutions, and the importance of analytical methods in supporting development programs and meeting expanding regulatory requirements. Continuous improvements in these analytical methods are crucial to address the evolving challenges in mRNA-based drug production and to maintain high standards of safety and effectiveness.","link":"https://www.brighttalk.com/webcast/10519/629083","status":"upcoming","duration":7200},{"date":"2025-02-11T08:30:00.000Z","id":621687,"channelId":10519,"thumbnail":{"alt":"Enhancing Sustainability in Biopharmaceutical Drug Development and Manufacturing","url":"https://cdn.brighttalk.com/ams/california/images/communication/621687/image_1000828.jpg?width=640\u0026height=360"},"title":"Enhancing Sustainability in Biopharmaceutical Drug Development and Manufacturing","description":"This presentation will cover the current sustainability challenges for biopharma industry and how biopharma industry should prepare to solve for this looming sustainability challenges. This talk will also indicate on some aspects of future of manufacturing processes through technological evolution.\n\nFinally, the audience will also hear on a case study which stresses on how a technology evolution and process development can enhance the sustainability issues of Biomanufacturing. \n\nThe second presentation will cover guidance of adopting Phase appropriate orthogonal high-end tools in early-stage product development and Selection of analytical tools for expedited biopharmaceutical development. This talk will provide overview on Significance of High throughput and sensitive analytical tools from Clone to Formulation ranking. This talk will also cover the contemporary challenges in HCP by ELISA and approach to defeat these challenges by alternate approach.","link":"https://www.brighttalk.com/webcast/10519/621687","status":"upcoming","duration":7200},{"date":"2025-01-29T15:00:00.000Z","id":610062,"channelId":10519,"thumbnail":{"alt":"Fully Continuous Purification Platform Using Nanoparticles...","url":"https://cdn.brighttalk.com/ams/california/images/communication/610062/image_1008248.jpg?width=640\u0026height=360"},"title":"Fully Continuous Purification Platform Using Nanoparticles...","description":"Full title: Fully Continuous Purification Platform Using Nanoparticles With Ligands and Ultrafiltration\n\nWe present on a truly continuous purification technique with potential to reduce costs-of-goods for mAbs, over conventional chromatography-based separations.\n\nWe demonstrate the development and proof-of-concept application of a self-assembling affinity nanoparticle to enable affinity ultrafiltration of mAb from an impure mixture.\n\nThis technique leverages counter current flow ultrafiltration, concentration gradients between feed and product, in a series of filters representing the phases of the process. Impurity clearance can remain high while minimizing overall buffer consumption and consequently PMI for water.\n\nOverall, these data represent an early advancement toward the development of a truly continuous, counter-current, and column-free method to capture and purify mAb without expensive conjugated resins. We envision further expansion of commercially available nanoparticles towards modality and application specific designs to enable PMI savings across therapeutic areas, delivering lower cost medicines to patients.","link":"https://www.brighttalk.com/webcast/10519/610062","status":"upcoming","duration":7200},{"date":"2025-01-16T15:00:00.000Z","id":624135,"channelId":10519,"thumbnail":{"alt":"Leveraging Instrumentation to Accelerate Release Testing \u0026 Minimize Human Input","url":"https://cdn.brighttalk.com/ams/california/images/communication/624135/image_1013924.jpg?width=640\u0026height=360"},"title":"Leveraging Instrumentation to Accelerate Release Testing \u0026 Minimize Human Input","description":"Presented by Therese Choquette, Head of Analytical and Translational Sciences at Tigen Pharma\n\nThis talk will focus on the analytical testing needed for the release of cell and gene therapy products. A lot of focus has been on improvements and automation of equipment used in manufacturing of cell therapies such as bioreactors. However, to improve and speed up the release testing, this needs to be done also on the analytical side.\n\nToday, in most Quality Control labs, the instruments and methods that are used for in-process and release testing are high throughput (bigger sized instruments) and require experienced analysts for the execution of the test, for example in flow cytometry. The preparation of the sample involves manual manipulation, such as for the potency assay, sometimes very extensive and lengthy before ready to be tested. Once the test is performed, the data needs to be analyzed and calculated for the reportable results, it may for example be from an ELISA for cytokines or the genetic transduction by PCR. The entire procedure from the sample preparation to the data analysis for the results provides opportunities for errors, and the manipulation of the samples can have an impact on the cells. This may decrease the precision of the assay and potentially cause Out Of Specification and delay of product release. \n\nDepending on each specific product, different analytical tests and assays are required for the release of the product. However, safety tests for determination of absence of mycoplasma, endotoxin, and bacterial and fungal contamination are mandatory for all products. No matter the type of tests or assays, there is a need for faster and less hands-on technology. Using automated instruments and methods with less manipulation of the sample and automated data analysis, offers opportunities to reduce time and costs for the release testing, as well as providing assays with improved performance and less prone for errors.","link":"https://www.brighttalk.com/webcast/10519/624135","status":"upcoming","duration":7200},{"date":"2024-11-14T15:00:00.000Z","id":622712,"channelId":10519,"thumbnail":{"alt":"Process Equipment Related Leachable Compounds - 3 Case Studies","url":"https://cdn.brighttalk.com/ams/california/images/communication/622712/image_1008970.jpg?width=640\u0026height=360"},"title":"Process Equipment Related Leachable Compounds - 3 Case Studies","description":"Process Equipment Related Leachable Compounds – 3 case studies\n\nCase 1: Over sterilized filter, 3 days instead of 3 hours – process leachable compounds in the parenteral drug product\n\nCase 2: Solid, white, 5 mm flakes in process equipment – effects on the parenteral drug products\n\nCase 3: What is wrong with the process equipment? – PERL investigation continued as a stopper related leachable analyses.","link":"https://www.brighttalk.com/webcast/10519/622712","status":"recorded","duration":6744},{"date":"2024-11-07T15:00:00.000Z","id":621949,"channelId":10519,"thumbnail":{"alt":"Achieving Fully Continuous End-to-End Processing","url":"https://cdn.brighttalk.com/ams/california/images/communication/621949/image_995398.jpg?width=640\u0026height=360"},"title":"Achieving Fully Continuous End-to-End Processing","description":"The current “continuous” downstream is a complex sequence of batch operations, almost a slight-of-hand continuous process that cannot take advantage of most of the value of truly continuous processes. While the current chromatography-based processes are sufficient to bring the cost of goods manufactured down by 40-60%, there is significant benefit from a truly continuous process.\n\nWe have demonstrated the use of recombinant affinity nanoparticles and complexes in a dialysis and tangential-flow filtration-based capture step. The development of the nanoparticles is challenging and we have tested over 100 nanoparticles evaluating expression, their ability to bind antibody, and their stability under acidic elution conditions. We believe many are economical enough to allow commercial use, though we have found many to have suboptimal stability at low pHs and that most of the high-pH constructs have significantly reduced capacity. Finally, we have found that the wide pore-size distribution on UF membranes have allowed 10% or more of the nanoparticle to pass through along with the antibody.\n\nWe will discuss general methods we’ve used to quickly evaluate nanoparticles including small scale, ~1000kDa MWCO dialysis, and centrifugal dead-end ultrafiltration. We will also discuss associated analytical techniques including mass photometry, SEC, and native blue electrophoresis.\n\nThe data we have generated allows us to be confident that these methods are worth continued effort. Truly continuous processing allows the reuse of solutions from a cleaner downstream to a dirtier upstream. This reuse of solution, and the continuous nature of the process, should decrease cost of goods beyond the current ICB processes while increasing the level of sustainability.","link":"https://www.brighttalk.com/webcast/10519/621949","status":"recorded","duration":3303},{"date":"2024-10-30T14:00:00.000Z","id":612992,"channelId":10519,"thumbnail":{"alt":"Evaluating Analytical Strategies to Quantify Capsid Titre...","url":"https://cdn.brighttalk.com/ams/california/images/communication/612992/image_1004100.jpg?width=640\u0026height=360"},"title":"Evaluating Analytical Strategies to Quantify Capsid Titre...","description":"Full title: Evaluating Analytical Strategies to Quantify Capsid Titre: Towards a Platform-Method Approach to Accelerate AAV Drug Product Development\n\nTraditional capsid titre methods rely on ELISA which commonly suffers from long turnaround times, low throughput, and large volume sample requirements. This limits the application of ELISA-based methods to routine analysis, thus requiring development of alternative high-throughput (HTP) capsid titre methods. We have performed a comprehensive assessment on currently available orthogonal capsid titre methods using multiple serotypes at concentration range relevant in IND-enabling preclinical and first-in-human (FIH) clinical studies.","link":"https://www.brighttalk.com/webcast/10519/612992","status":"recorded","duration":3612},{"date":"2024-10-29T14:00:00.000Z","id":613602,"channelId":10519,"thumbnail":{"alt":"The Factory of the Future","url":"https://cdn.brighttalk.com/ams/california/images/communication/613602/image_978309.jpg?width=640\u0026height=360"},"title":"The Factory of the Future","description":"The advancement in technologies and innovative thinking are profoundly changing biopharmaceutical drug production industry holistically, giving rise to “the factory of the future.” What will the factory of the future with respect to its structure, technologies, processes, and drug product delivery to the patient be? What enablers will manufacturers need in terms of strategy, leadership, employee skills, IT/OT infrastructure, regulatory oversight, and suppliers to make this a reality?\n\nThe factory of the future is an innovation vision on how manufacturers should enhance production by transforming manufacturing in three dimensions: plant structure, plant digitization, and plant processes.\n\nHaving a holistic vision of the process\n\nDesigning and implementing a flexible framework\n\nEvaluating and implementing proper technology and skill\n\nEmphasizing safety, quality, purity, efficacy and regulatory mandates\n\nThe bottom line – delivering ROI","link":"https://www.brighttalk.com/webcast/10519/613602","status":"recorded","duration":3354},{"date":"2024-10-22T14:00:00.000Z","id":613603,"channelId":10519,"thumbnail":{"alt":"Defining Patient-Centric Specification in a Risk-Based Control System","url":"https://cdn.brighttalk.com/ams/california/images/communication/613603/image_982162.jpg?width=640\u0026height=360"},"title":"Defining Patient-Centric Specification in a Risk-Based Control System","description":"Defining limits for analytical method outputs is a central element of a control strategy. Traditional approaches usually focus on ensuring process consistency, while in more advanced approaches the understanding of structural-function relationships are utilized. This enables definition of patient centric limits that focus on controlling the impact of CQAs on product efficacy and patient safety. In certain cases, those limits and can be defined independent from a specific analytical method and where indicated can extend beyond a therapy specific clinical history. Process consistency control and change management are an integral part of the patient-centric specification and risk-based control strategy approach. The presentation will provide some practical examples for the definition of patient-centric specifications and process consistency control.","link":"https://www.brighttalk.com/webcast/10519/613603","status":"recorded","duration":3206},{"date":"2024-10-02T14:00:00.000Z","id":620145,"channelId":10519,"thumbnail":{"alt":"Downstream Platform Process Development for AAV viral vectors...","url":"https://cdn.brighttalk.com/ams/california/images/communication/620145/image_992210.jpg?width=640\u0026height=360"},"title":"Downstream Platform Process Development for AAV viral vectors...","description":"Full title: Downstream Platform Process Development for AAV viral vectors; Challenges and Opportunities\n\nThis talk is designed for professionals and researchers from the scientific community, particularly those engaged in industry applications. In this session, I will delve into the concept of platformability in the context of AAV downstream processes. I will examine the opportunities this approach offers for enhancing efficiency, scalability, and reproducibility in viral vector production.\n\nKey topics will include: -\n\nDefining Platformability: Understanding its significance in streamlining AAV production.\n\nTechnological Opportunities: Innovative methods and tools available for optimizing downstream processes.\n\nChallenges and Solutions: Identifying common obstacles and discussing potential strategies to overcome them.\n\nAttendees will gain valuable insights into the latest advancements and practical solutions for developing robust downstream processes, positioning them at the forefront of AAV vector production technology.","link":"https://www.brighttalk.com/webcast/10519/620145","status":"recorded","duration":1963},{"date":"2024-10-01T14:00:00.000Z","id":620048,"channelId":10519,"thumbnail":{"alt":"Adventitious Agent Testing For MMV: How Much Do We Really Know?","url":"https://cdn.brighttalk.com/ams/california/images/communication/620048/image_1002672.jpg?width=640\u0026height=360"},"title":"Adventitious Agent Testing For MMV: How Much Do We Really Know?","description":"Maria Farcet, Head of Cell Culture, Virus Models \u0026 Serology in the Global Pathogen Safety / Global Quality team at Takeda\nPresenting: Adventitious Agent Testing For MMV: How Much Do We Really Know?\n\nAmina Cherif Louazani, PhD, Viral Safety Manager at PathoQuest\nPresenting: Advancing Viral Safety in Biologics: Comprehensive Virus Detection with iDTECT® Transcriptome NGS-Based Assay\n\nDr. Denise Teber, Scientific Expert of the PCR department at Charles River Laboratories\nPresenting: Viral safety testing of human cell lines used for biopharmaceutical manufacturing.","link":"https://www.brighttalk.com/webcast/10519/620048","status":"recorded","duration":8261},{"date":"2024-09-23T14:00:00.000Z","id":614021,"channelId":10519,"thumbnail":{"alt":"Medical Device Chemical Toxicological Risk Assessments...","url":"https://cdn.brighttalk.com/ams/california/images/communication/614021/image_998919.jpg?width=640\u0026height=360"},"title":"Medical Device Chemical Toxicological Risk Assessments...","description":"Medical device chemical toxicological risk assessment is challenging because the risk assessor often needs to consider the many types of device intended uses, many types of materials used in design and manufacturing, and many types of intentional and unintentional chemicals that are or could be present in the final finished device. Medical device intended uses include the type of tissue contact, the contact frequency and duration, and the susceptibility of the device user to chemical exposure. Material factors include the material type (e.g., alloy, polymeric, ceramic, or natural), material properties (e.g., alloy surface characteristics, polymer plasticity, or polymer manufacturing process), and material chemical composition (e.g., chemical formulation, potent toxicants (if present), and the rate and duration of release). How to apply these considerations is described in the U.S. Food and Drug Administration (FDA) 2023 guidance Use of International Standard ISO 10993-1, “Biological evaluation of medical devices: Part 1: Evaluation and testing within a risk management process,” International Standard Organization (ISO) 10993 series, and ISO 14971. This presentation will describe how chemical toxicological risk assessment fits into the overall medical device biological risk management process (i.e., risk analysis, risk evaluation, or risk control). Additionally, what medical device use and chemical toxicological information to consider from the U.S. FDA 2023 guidance and ISO documents when estimating chemical toxicological risk will be covered, such as: approaches for characterizing the applicable chemical specific harm(s), estimating an exposure dose, deriving a tolerable intake (TI), and other critical factors to consider that could be useful in the determination of whether exposure to a medical device chemical presents a tolerable risk or could present a possible toxicological risk.","link":"https://www.brighttalk.com/webcast/10519/614021","status":"recorded","duration":9535},{"date":"2024-09-17T14:00:00.000Z","id":610490,"channelId":10519,"thumbnail":{"alt":"Established Conditions in Analytical Procedure: Overview, Regulatory Examples","url":"https://cdn.brighttalk.com/ams/california/images/communication/610490/image_994734.jpg?width=640\u0026height=360"},"title":"Established Conditions in Analytical Procedure: Overview, Regulatory Examples","description":"Full title: Established Conditions in Analytical Procedure: Overview, Regulatory Examples and an FDA Laboratory Study\n\nEstablished conditions (ECs) are manufacturing and control elements considered necessary to assure product quality (e.g., ECs in manufacturing process) and to help assure method performance (e.g., ECs in analytical procedures). ECs in analytical procedures help to maintain reliable results that can ensure the efficient product control strategy during the product life cycle. Changing ECs in analytical procedures may necessitate a certain level of regulatory activity and the level of regulatory activity can be different depending on the strategy defining ECs and the extent of changes. The presentation will first provide a high-level overview of harmonized scientific risk-based approaches for identifying ECs and determining the corresponding reporting categories based on scientific principles described in ICH Q12 and Q14 guidelines. Then, two regulatory examples involving ECs in analytical procedures will be discussed. It is noteworthy mentioning that both parameter and performance-based ECs in an analytical procedure are defined in these two examples. The last part of the presentation will be an FDA laboratory study on a mass spectrometry method for a recently identified NDSRI (Nitrosamine drug substance-related impurity). In this case study, analytical variables and method robustness were investigated according to recommendations from the ICH Q2R2 (draft) Guideline. Based on the impact of each variable on method performance, categorical and numerical ECs were proposed.","link":"https://www.brighttalk.com/webcast/10519/610490","status":"recorded","duration":7818},{"date":"2024-09-16T04:30:00.000Z","id":624241,"channelId":10519,"thumbnail":{"alt":"Successful Scale Up of a High Yielding Viral Vector Suspension Platform to 500 L","url":"https://cdn.brighttalk.com/ams/california/images/communication/545700/image_855050.jpg?width=640\u0026height=360"},"title":"Successful Scale Up of a High Yielding Viral Vector Suspension Platform to 500 L","description":"As gene therapies move toward commercialization, the journey to manufacture a high-quality product while achieving economies of scale and reducing facility footprint, can be challenging. Developing and optimizing your process development early on is critical for your company’s long-term success.\n\nIn this webinar, we will present our scalable integrated platforms for viral vector production in both adherent and suspension cell cultures. Key factors to consider in choosing the right technology for scaling up will be discussed in terms of factors such as cost, time, and risk. You will hear from Andelyn’s process development team and Pall’s Accelerator℠ process development experts on their strategy, proven methods, and bioprocess solutions, and on how they scaled up an Adeno-Associated Virus (AAV) manufacturing process using FectoVIR®-AAV transfection reagent to up to 500 L.\n\nAttendees will learn how to:\n\nAchieve versatility with a scalable, single-use end-to-end platform\n\n\nOptimize small-scale expression systems into a scalable process\n\n\nAchieve goals faster and better with Pall process development team","link":"https://www.brighttalk.com/webcast/10519/624241","status":"recorded","duration":6753}],"envVariables":{"hostUrl":"https://www.brighttalk.com","gtmId":"GTM-WL9H26","envValue":"prod","cloudinaryEnv":"brighttalkprod","staticAssetCdnUrl":"https://assets.brighttalk.com","nextPublicSentryDSN":"https://85b928fa6c7a4e9985f029323783cd54@o311348.ingest.sentry.io/5438623"}},"__N_SSP":true},"page":"/[channelId]/[webcastId]","query":{"utm_source":"888PublishingLtd","utm_medium":"brighttalk","utm_campaign":"623717","channelId":"10519","webcastId":"623717"},"buildId":"1079","assetPrefix":"/webcast","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[12910,75479,93394],"gssp":true,"appGip":true,"scriptLoader":[]}</script><script> window.dataLayer = window.dataLayer || []; dataLayer.push({ 'brighttalk-page-name': 'webcast', 'brighttalk-portal-is-logged-in': false });</script><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-WL9H26');</script><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-WL9H26" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript></body></html>